YWP
CRSP icon

YorkBridge Wealth Partners’s CRISPR Therapeutics CRSP Stock Holding History

YorkBridge Wealth Partners’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-100
Closed -$5K – 271
2019
Q2 		$5K Hold
100
– – ﹤0.01% 655
2019
Q1 		$4K Hold
100
– – ﹤0.01% 665
2018
Q4 		$3K Buy
+100
New +$3.48K ﹤0.01% 660

Other funds holding CRSP

VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

YorkBridge Wealth Partners's CRSP Position: Q3 2019 in Review

YorkBridge Wealth Partners sold out of CRISPR Therapeutics (CRSP) in Q3 2019, closing a stake of 100 shares — an estimated $5K sold.

YorkBridge Wealth Partners first reported a position in CRSP in Q4 2018 and held it in 3 quarters. The position peaked at $5K in Q2 2019. 182 funds tracked by Wall St. Rank hold CRSP as of Q3 2019.

  • YorkBridge Wealth Partners reported no remaining CRISPR Therapeutics position as of Q3 2019 after selling out during the quarter.
  • YorkBridge Wealth Partners sold 100 CRISPR Therapeutics shares in Q3 2019, an estimated $5K.
  • YorkBridge Wealth Partners first reported a position in CRISPR Therapeutics in Q4 2018 and held it in 3 quarters.
  • YorkBridge Wealth Partners's CRISPR Therapeutics position peaked at $5K in Q2 2019.
  • 182 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2019.

Based on YorkBridge Wealth Partners's 13F filing for Q3 2019, filed 21 Oct 2019.